Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study
Y. Brandberg et al., Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study, EYE, 14, 2000, pp. 839-846
Purpose To investigate psychological reactions and quality of life among pa
tients with posterior uveal melanoma.
Methods Consecutive patients with uveal malignant melanoma (99/106), referr
ed to St Erik's Eye Hospital 1995-1996, treated with rutheniuim plaque radi
otherapy (n = 50) or enucleation (n = 49), were included in this non-random
ised prospective comparative study. Questionnaires were completed before tr
eatment (Hospital Anxiety and Depression Scale, HAD scale) and 2 and 12 mon
ths after diagnosis including the HAD scale, the Impact of Event Scale and
the EORTC QLQ-C30. A disease-specific questionnaire was included 12 months
after diagnosis. Between-group differences were analysed by chi-square, Stu
dent's t-test and ANOVA.
Results A majority of the patients reported reduced 'Quality of Life' (72-8
5%), 'Emotional functioning' (60-74%) and 'Cognitive functioning' (51-61%).
'Fatigue' was the most frequently reported symptom (61-72%) followed by 'I
nsomnia' (43-58%). Anxiety and depressive symptoms were relatively frequent
up to 1 year after treatment, but the levels of anxiety decreased during t
he first year after treatment. Disease and treatment-related problems were
reported in both treatment groups 1 year after diagnosis. Enucleated patien
ts had more problems with appearance and judging distances, whereas those t
reated with radiotherapy reported vision impairment to a higher extent.
Conclusions Enucleated patients reported high levels of emotional distress,
problems with appearance and judging distances during the first year after
treatment. Patients treated with radiotherapy reported similar levels of q
uality of life and emotional problems, but more problems with visual impair
ment. These differences in impact on disease-related functioning should be
taken into account when treatment options are discussed.